VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALGS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALGSAligos Therapeutics, Inc.
$2.10$13M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ALGS logo

Aligos Therapeutics, Inc.

ALGS
NASDAQ · Vaccines & Infectious Disease
$2.10
At close - Nov 13, 4:00 PM EST - USD
Market Cap$13M
P/E-0.3x
52W High$13.69
Volume57.43K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Persistent Clinical Burn Challenges Aligos Liquidity Position

Aligos Therapeutics faces a precarious financial outlook as its clinical-stage pipeline continues to generate significant losses, with R&D expenses reaching $23.4M in 2026Q1 against minimal revenue.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ALGS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

8/12 Beats

EPS beat 8 of last 12 quarters

02

Valuation risk

-101% Peers

P/E is 101% below peer median

03

Market leadership

RS 6 · Lag

Laggard (Underperforming 94% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 6

Market performance

Price History →

Trailing total returns as of 11/16/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ALGS-77.00%
S&P 500 (^GSPC)+10.42%
1-Year Return
ALGS-65.40%
S&P 500 (^GSPC)+12.25%
3-Year Return
ALGS-86.00%
S&P 500 (^GSPC)+75.74%
5-Year Return
ALGS-99.50%
S&P 500 (^GSPC)+65.46%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$2M-44.6% YoY
Net income FY25
-$24M+81.6% YoY
Free cash flow FY25
-$83M-2.6% YoY
Operating margin FY25
-4024.9%-1765.0 pts YoY
ROIC (FY25)-163%
Avg ROIC 5Y-1561.3%
ROE (TTM)-206.3%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate8/12 (67%)
Revenue Beat Rate7/12 (70%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 6, 2026
-$2.09+8.3%
vs -$2.28
$3M-40.8%
vs $5M
Q3 2026
Aug 6, 2026
-$0.14+87.2%
vs -$1.09
$28M+12.6%
vs $25M
Q2 2026
May 7, 2026
-$2.21+3.5%
vs -$2.29
$3M+1032.0%
vs $250,000
Q2 2026
Mar 5, 2026
-$1.91+23.2%
vs -$2.49
$169,000-61.6%
vs $440,000
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
GlobeNewsWire·Nov 6, 2026
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2026.

GlobeNewsWire·Nov 5, 2026
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from five presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO.

GuruFocus·Oct 11, 2026
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will host an investor call on Monday, October 12, 2026 at 8:

GlobeNewsWire·Oct 5, 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced five abstracts have been accepted for presentation at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting® 2026, being held November 5 – 9, 2026 in Denver, CO. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting.

Filtered for Aligos Therapeutics, Inc.More Headlines
04

Compare before deciding

Benchmark ALGS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Aligos Therapeutics, Inc. (ALGS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ALGS logoALGSAligos Therapeutics, Inc.Current
$2.10$13M-0.33-44.59%-197.01%-206.3%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$47.78$6.73B-9.32-45.65%-160.64%-172.62%—
HALO logoHALOHalozyme Therapeutics, Inc.
$100.27$11.89B25.3337.55%26.93%544.26%—
RCUS logoRCUSArcus Biosciences, Inc.
$17.43$2.19B-4.99-4.26%-445%-90.04%—
GILD logoGILDGilead Sciences, Inc.
$168.08$208.68B-54.432.39%-12.47%-21.84%1.9%
VRTX logoVRTXVertex Pharmaceuticals Incorporated
$538.60$136.7B34.579.57%30.61%20.08%—

Compare ALGS vs Peers

Aligos Therapeutics, Inc. (ALGS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ARWR

Most directly comparable listed peer for ALGS.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare ALGS against a more recognizable public peer.

Peer Set

Compare Top 5

vs ARWR, HALO, RCUS, GILD

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ALGS SEC Filings & Documents

Aligos Therapeutics, Inc. (ALGS) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 6, 2026·SEC

Material company update

Aug 6, 2026·SEC

Material company update

Jun 26, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 5, 2026·SEC

FY 2025

Mar 10, 2025·SEC

FY 2024

Mar 12, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 6, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when ALGS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ALGS Frequently Asked Questions

Aligos Therapeutics, Inc. (ALGS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Aligos Therapeutics, Inc.'s revenue?

Aligos Therapeutics, Inc. (ALGS) reported $33.6M in revenue over the trailing twelve months. Revenue was $2.2M in fiscal year 2025.

How fast is Aligos Therapeutics, Inc. growing?

Aligos Therapeutics, Inc. (ALGS) grew revenue by 1171.6% over the trailing twelve months, compared with the twelve months before.

Is ALGS profitable?

No. Aligos Therapeutics, Inc. (ALGS) reported a net loss of $66.3M over the trailing twelve months.

Dividend & Returns
What is ALGS's return on equity?

Aligos Therapeutics, Inc. (ALGS) had a return on equity (ROE) of -206.3% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Aligos Therapeutics, Inc.'s free cash flow?

Aligos Therapeutics, Inc. (ALGS) had negative free cash flow of $68.7M over the trailing twelve months.

What if you invested $1,000 in ALGS back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →